Skip to main content
10 Jun 2025
1 minute read

Deloitte Tech Trends 2025: A Life Sciences & Healthcare perspective

Unveiling the next wave of medtech and biopharma innovation

Embrace the future of digital innovation in Life Sciences. Our sector-specific analysis of Deloitte’s 16th annual Tech Trends report highlights six pivotal technology trends reshaping the medtech and biopharma sectors. Explore how these advancements may influence your business strategies and operations now and in the future.

Download the full report "Deloitte Tech Trends 2025: A Life Sciences & Healthcare Perspective"
1 MB PDF

 

The Life Sciences and Healthcare (LSHC) landscape is rapidly evolving, driven by technological advancements that are reshaping how companies research, develop, and deliver treatments and devices for healthcare professionals, healthcare organisations and, ultimately, for patients. This LSHC perspective of our Tech Trends 2025 report dives into the forces shaping this transformation, exploring how technology is being implemented and its implications for the LSHC industry.

We highlight six key areas predicted to be critical to technology in the coming 18-24 months. A key theme at the centre of these trends is the ubiquitous nature of AI, which has already demonstrated its potential as a transformative force within Life Sciences and Healthcare. Its impact is increasingly evident in areas as diverse as drug discovery, the development of smart devices, supply chain optimisation, personalised patient care, and core technology legacy modernisation – to name a few.
 

Navigating the Future of Technology in LSHC

The LSHC industry perspective builds on the Tech Trends 2025 report. In providing a specific industry view, it highlights relevant use cases and examples that are already transforming the industry. The overarching theme is the ubiquity of AI and its integral role in every facet of the LSHC landscape, with its potential to drive innovation, enhance efficiency, and improve patient outcomes.


Through real-world examples and use cases, this perspective provides insight into how each aspect of the technology landscape is being shaped and how Life Sciences and Healthcare organisations are leveraging AI to gain a competitive edge.

How are LSHC exploring this trend?

  • Accelerated biopharma research: AI is streamlining drug discovery, from automating literature reviews to accelerating software development. Agentic AI systems designed for autonomous action can significantly increase the success rates for AI-discovered drugs.
  • Resilient supply chains: by leveraging predictive capabilities and enabling autonomous corrective actions, AI can create more resilient, ‘self-healing’ supply chains leading to smoother operations and more agile responses to changing dynamics.
  • Personalised experiences: Agentic AI can empower organisations to deliver personalised experiences by analysing vast customer datasets to understand individual needs and preferences; leading to more tailored, cost-effective treatments

How are LSHC exploring this trend?

  • Improving the efficiency of pharma R&D: spatial computing can be used to visualise molecules in 3D, enabling more efficient drug design and virtual testing, with virtual environments enhancing patient recruitment and data collection.
  • Improving healthcare operations: Healthcare organisations are exploring the use of virtual representations to experiment with different care models, assessing the potential impact on factors like wait times and patient access before implementing changes.
  • Revolutionising MedTech design: digital twins can enable virtual prototyping and testing, leading to faster innovation cycles. Simulations can be used to optimise manufacturing and repair processes, improving efficiency and accuracy.

How are LSHC exploring this trend?

  • Real-time diagnostic tools: NPUs powering portable diagnostic tools, real-time patient monitoring devices, and even smart prosthetics powered could lead to faster diagnoses, personalised treatments, and improved accessibility.
  • Robotic transformation: humanoid robots could reshape how we approach patient care and medical research, from handling hazardous waste to assisting in operating rooms.

How are LSHC exploring this trend?

  • Driving value with centres for enablement (C4Es): C4Es are breaking down traditional IT silos and empowering technology innovation. By providing access to low-code/no-code platforms and a self-service mindset, C4Es are helping organisations become more agile and responsive to changing needs.
  • GenAI is fundamentally reshaping the IT function: automating most tasks. from code generation to testing and documentation, freeing IT professionals to focus on innovation and higher-value activities as carefully crafted guardrails and strategies around prompting, mitigate risk and output hallucinations.
  • The evolving IT function: the democratisation of AI enables IT departments to evolve shaping AI business strategies, guiding ‘buy vs. build’ decisions, and ensuring value realisation. Ultimately empowering organisation-wide innovation through a decentralised, AI-powered ecosystem.

How are LSHC exploring this trend?

  • Regulation-driven change: the widespread adoption of quantum-resistant solutions will ultimately be driven by evolving regulatory requirements and industry standards.
  • Future-proofing quantum device security: as medical devices become increasingly sophisticated and interconnected, building products with quantum-resistant security can provide a competitive advantage and build consumer trust.
  • Ensuring confidentiality of sensitive information: LSHC organisations handle vast amounts of highly sensitive data, from patient records to intellectual property. Adopting quantum-secure practices is crucial for maintaining the confidentiality of this information and consumer trust.

How are LSHC exploring this trend?

  • Accelerating transformation: By automating the extraction of data and documentation from legacy systems, organisations can gain rapid insights into functionality, data mapping, service dependencies, and purpose, reducing analysis from days to seconds.
  • Creating an AI-enhanced core: off-the-shelf, AI-embedded, solutions are becoming increasingly accessible, providing organisations, with automation and intelligence capabilities. Organisations with mature AI strategies and appropriate licensing models can extract value from these solutions.
  • Architecting and organising for AI: adaptable organisations that can seamlessly integrate existing and emerging AI tools will be in the best position to harness the full potential of AI. ‘Buy vs build’ decisions come with significant cost, control and flexibility implications.

Stay ahead of your game with the future of tech

Explore the technologies shaping the future of the Life Sciences and Healthcare industry and understand their impact on your organisation. Delve into the Life Sciences and Healthcare (LSHC) Tech Trends 2025 report to discover how these trends can unlock new opportunities for you, your organisation, your customers and your patients.

Did you find this useful?

Yes
No

Thanks for your feedback

Your feedback is important to us

To tell us what you think, please update your settings to accept analytics and performance cookies.

Need help updating cookies?

Contact us

Hannah Hayward

Hannah Hayward

Partner, CIO Programme Chair
+41 58 279 6175
Yousif Al-Adhami

Yousif Al-Adhami

Technology Advisory Leader
+41 58 279 6757
Gurneesh Cheema

Gurneesh Cheema

Director | Life Sciences and Healthcare, Technology Strategy & Transformation
+41 58 279 6324

Our Thinking

Tech Trends 2025

In Deloitte’s 16th annual Tech Trends report, AI is the common thread of nearly every trend. Moving forward, it will be part of the substructure of everything we do.

Important IT considerations for successful M&A transactions in Life Sciences

Understanding the complex role of IT in the Life Sciences industry, identifying key focus areas to address, and deeply exploring each area will help organisations accelerate and effectively execute M&A transactions.

Future of Customer Engagement

For many years the Life Sciences industry has envisioned the possibilities of delivering high-impact, trusted, and unique customer experiences but has often fallen short of fully realising the ambition. What makes now the moment to make this change happen? 

Accelerating the Future

Welcome to the fourth of a series of life sciences and healthcare predictions reports, comprising ten predictions exploring how the world could look in 2030, what it might feel like for different stakeholders in the health ecosystem, the evidence today that informs our views of tomorrow and how AI technologies, specifically GenAI, might help bring the future closer.
Perspective

Measuring the return from pharmaceutical innovation 2025

The 15th edition of the Pharma R&D ROI study analyses the forecast internal rate of return (IRR) for the top 20 biopharma companies, revealing a second year of growth to 5.95% lead by GLP-1s and other new high-value products.
Research
10 minute read

The Future of Health in Europe

To ensure citizens’ future health and well-being, Europe will need to chart a new, cost-effective and sustainable approach to healthcar
Perspective